MAPT and early-onset autosomal dominant Alzheimer disease: In Alzheimer’s disease research, for example, transgenic lines overexpressing human APP, PSEN1, or MAPT (Tau) have been developed to study amyloid plaque formation, Tau hyperphosphorylation, and their downstream effects on neuronal viability and cognitive function [146].